Adlai Nortye (ADR)
Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.
$13.82
After-hours close+0.08 (+0.58%)
At close$13.74(−4.05%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.04 | −$0.04 | +7.9% |
| Apr 2026 | −$0.11 | −$0.18 | −71.4% |
| Dec 2025 | −$0.18 | −$0.18 | 0.0% |
| Aug 2025 | −$0.18 | −$0.18 | 0.0% |
The latest year is open to everyone — the 13 quarters behind it read with an account. Sign in | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Jan 1970 | −$0.38 | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | −$0.04 | −$0.04 | +7.9% | $12.5M | $14.7M | +17.7% |
| Apr 10, 2026 | −$0.11 | −$0.18 | −71.4% | $10.0M | $5.3M | −47.0% |
| Dec 29, 2025 | −$0.18 | −$0.18 | 0.0% | $313.2K | — | — |
| Aug 7, 2025 | −$0.18 | −$0.18 | 0.0% | — | — | — |
The latest year is open to everyone — the 13 quarters behind it read with an account. Sign in | ||||||
| Apr 30, 2025 | ||||||
| Feb 26, 2025 | ||||||
| Aug 8, 2024 | ||||||
| Apr 20, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Jan 1, 1970 | −$0.38 | — | — | — | — | — |